poisar

Stocks · News reference

Steris Widens FY2027 Adj EPS Guidance from $11.10-$11.30 to $11.00-$11.30 vs $11.16 Est; Affirms FY2027 Sales Guidance of $6.352B-$6.411B vs $6.371B Est

Benzinga Newsdesk

Steris (NYSE:STE) widens FY2027 Adj EPS guidance from $11.10-$11.30 to $11.00-$11.30 vs $11.16 analyst estimate. Affirms FY2027 sales outlook from $6.352 billion-$6.411 billion to $6.352 billion-$6.411 billion vs $6.371

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

STE
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Na

    Steris (STE) Down 2.1% Since Last Earnings Report: Can It Rebound?

    STERIS reported strong Q1 fiscal 2027 results with adjusted EPS of $2.59 (up 10.7% YoY) beating estimates by 1.97%, driven by higher volume, pricing, and productivity across all segments. However, revenues of $1.49 billion missed consensus by 0.83%. The company reaffirmed its fiscal 2027 guidance for 7-8% revenue growth and $11.10-$11.30 adjusted EPS. Despite solid earnings, shares have underperformed the S&P 500 by 2.1% since the report.

    STEOPK